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Abstract
Background: The development of several disorders, such as cardiovascular diseases, diabetes and osteoporosis, has
been linked to suboptimal dietary magnesium (Mg) intake. In this context, a number of studies have tried to
investigate which Mg compounds are best suited for Mg supplementation. Results suggest that organic Mg
compounds are superior to the inorganic Mg oxide in terms of bioavailability, but a reliable statement cannot
yet be made due to systematic differences in the applied study designs.
Methods: This single-center, randomized, open, 2-period, 2-supplementation, 2-sequence, single-dose, cross-over
study was conducted in 20 healthy male subjects of Caucasian origin to investigate and compare the bioavailability of
Mg citrate, an organic Mg compound, and Mg oxide, an inorganic Mg compound. In order to reliably assess
the bioavailability of both Mg compounds, subjects were supplemented with magnesium to saturate their
Mg-pools before administration of each study product. The bioavailability of both Mg compounds was then
assessed by measurement of the renally eliminated Mg quantity during an interval of 24 h after single-dose
Mg administration (Ae 0-24h) as primary endpoint. Additionally, the Mg concentrations in a subset of leukocytes, in
erythrocytes and in serum were measured on an exploratory basis.
Results: After administration, Ae 0-24h of magnesium was higher for Mg citrate than for Mg oxide. Ae 0-24h for both
study products was compared by analysis of variance (ANOVA), revealing an adjusted mean difference of 0.565 mmol,
which was statistically significant at the 5% level (95% confidence interval of 0.212 to 0.918 mmol, p = 0.0034). Besides,
serum Mg concentrations were statistically significantly higher for Mg citrate than for Mg oxide at several time points
after administration. No statistically significant difference was shown in intracellular Mg contents.
Conclusions: This study confirms former study results showing a higher bioavailability of the organic Mg compound
Mg citrate compared to Mg oxide. It can be concluded that Mg citrate, similar to other organic Mg compounds, may
be more suitable than Mg oxide to optimize the dietary magnesium intake.
Trial registration: Retrospectively registered with the Australian New Zealand Clinical Trials Registry
(ACTRN12615001268538) on November 19, 2015.
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Background
Magnesium (Mg) is an essential electrolyte and plays a
central role in various cellular functions [1]. Over the
last 30–40 years, the dietary intake of Mg has declined
in many industrialized countries due to changes in food
preparation and nutritive behavior [2]. Studies suggest
that wide sections of the population are at risk of devel-
oping chronic latent Mg deficiency [3–5].
Suboptimal dietary Mg intake has been implicated in
the development of several disorders, such as cardiovas-
cular diseases, diabetes and osteoporosis [2, 6, 7], under-
lining the importance of sufficient magnesium intake.
Several oral preparations to supplement dietary Mg in-
take are currently available on the market. They differ in
the type of dosage form or the type of Mg compound
used, which can be inorganic (e.g., Mg oxide) or organic
(e.g., Mg citrate).
Human studies have tried to investigate which Mg
compounds are best suited for Mg supplementation by
determining and comparing their respective bioavailability
[8–14]. Their results suggest that Mg supplementation
with organic magnesium compounds such as Mg citrate,
Mg aspartate and Mg aspartate-hydrochloride might be
more efficient than with the inorganic Mg oxide. However,
those results are difficult to compare due to systematic
differences in study design and analyses of parameters.
Measuring Mg absorption is complicated by the fact that
Mg physiologically occurs in several compartments of the
human body and the Mg serum concentrations, although
easily accessible, are extraordinarily well-regulated, mak-
ing it difficult to use serum concentration-time curves for
measuring bioavailability [15]. The amount of renally ex-
creted magnesium in Mg-replete individuals after an oral
Mg load has been proposed as a clinically relevant meas-
ure of Mg absorption [9, 14–17].
After administration of Mg and intestinal absorption,
the Mg-pools in the bones fill up first. Bone contains
about 60% of total body Mg, whereas the remaining
40% is stored in soft tissue [18]. Systemic Mg distribu-
tion highly fluctuates and the rate and extent of Mg ab-
sorption depend on the filling state of those Mg-pools.
The daily renal excretion of Mg depends on the
absorbed amount of Mg from the diet and on the filling
state of the Mg-pools. Transfer of magnesium from
serum into urine begins immediately when the pools
are saturated, about 1-2 h after absorption [16]. In con-
trast, the uptake of Mg into body organs is slow. As a
result, the replenishing of depleted Mg-pools requires a
supplementation with rather high amounts of magne-
sium over a relatively long time [16]. Therefore, an ad-
equate duration of Mg administration in order to
saturate the Mg-pools is essential when the bioavailability
of Mg is studied by renal excretion after oral administra-
tion of a Mg product [9, 13, 15, 16, 19].
In order to obtain consistent results and to reliably as-
sess bioavailability of both Mg compounds by measuring
the renally eliminated Mg quantity, subjects in this study
were first supplemented with magnesium to completely
fill their Mg-pools before study product administration.
During the initial Mg saturation phase of 5 days, sub-
jects received five single doses of 100 mg magnesium as
Mg citrate a day. An intermediate Mg saturation phase
of 2 days was introduced between the administrations of
the different study products to ensure that the Mg-pools
of the subjects remained filled. Additionally, subjects’
dietary Mg intake was standardized throughout the
study. Filling status of Mg-pools was examined by com-
parison of baseline Mg excretion after both Mg satur-
ation phases.
Comparability to formerly published results is warranted
by also analyzing the Mg content in blood serum and cel-
lular blood components (monocytes and lymphocytes as
well as erythrocytes). Inductively coupled plasma optical
emission spectrometry was used to determine Mg in urine
and monocyte and lymphocyte samples. Magnesium con-
tent in erythrocytes was determined by a combination of a
clinical chemistry method and flame atomic absorption
spectrometry, whereas the serum samples were analyzed
spectrophotometrically.
The aim of this study was to compare the bioavailabil-
ity of Mg oxide and Mg citrate after single-dose adminis-
tration following Mg saturation.
Methods
Study design and objectives
This study was conducted in Germany as a single-
center, randomized, open, 2-period, 2-supplementation,
2-sequence, single-dose, cross-over study to compare the
bioavailability of two different Mg compounds: Mg citrate
and Mg oxide. Both Mg compounds were provided as
capsules (please refer to the methods’ subsection study
products below for more information).
The bioavailability of magnesium was assessed by
measuring the renally eliminated Mg quantity during the
interval of 24 h after Mg administration (Ae 0-24h) as pri-
mary endpoint. Additionally, and on an exploratory
basis, the magnesium concentrations in a subset of leu-
kocytes (i.e., monocytes and lymphocytes) as well as in
erythrocytes and the magnesium concentration in blood
serum were measured (please refer to the methods’ sub-
section sample collection and analyses below for details
regarding the analytical methods).
All target parameters of the study were objective vari-
ables that could not be influenced by intention of the
study subjects. Due to the cross-over design, subjects
served as their own control for the parameters under in-
vestigation. The integration of a placebo group and the
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blinding of products administered were not considered
necessary.
Study subjects and eligibility criteria
A total of about 20 healthy male subjects of Caucasian
origin aged between 18 and 45 years (inclusive) were to
be included in this study. Only male subjects were eligible
because the female hormone estrogen affects Mg distribu-
tion and therefore Mg excretion [20].
Subjects were only included if they had a body mass
index (BMI) within the range of 18.0 to 29.0, a normal
blood pressure (systolic blood pressure ≥95 ≤ 140 mmHg
and diastolic blood pressure ≥55 ≤ 90 mmHg), a resting
pulse of ≥45 and ≤95 bpm, a normal digestion (i.e., no
current obstipation or diarrhea), a normal renal function
(serum-creatinine <1.2 mg/dL), an ECG recording with-
out clinically significant abnormalities and if they re-
ported no febrile or infectious illness for at least 7 days
prior to the Screening Visit.
Illnesses or use of medication with influence on renal
function (e.g., diabetes, diuretics), conditions which might
interfere with the absorption of the study products (e.g.,
cholecystectomy, bowel resection) or any gastrointestinal
complaints within 7 days prior to the Screening Visit were
considered criteria for exclusion. Additionally, subjects
presenting with symptoms of Mg deficiency (e.g., muscle
cramps or fasciculations) as determined by physical exam-
ination and anamnesis or any active physical disease
(acute or chronic) were excluded. Moreover, clinical
chemical, hematological or any other laboratory parame-
ters (i.e., urinalysis and serology) clinically relevant outside
the normal range as judged by the investigator were con-
sidered criteria for exclusion.
Those with any history of chronic or recurrent meta-
bolic, renal, hepatic, pulmonary, gastrointestinal, neuro-
logical, endocrinological, immunological, psychiatric or
cardiovascular disease and bleeding tendency were also
excluded. Moreover, a history of alcohol or drug abuse,
chronic gastritis, peptic ulcers, drug hypersensitivity,
asthma, urticaria or other severe allergic diathesis as well
as acute symptoms of hay fever were considered criteria
for exclusion.
Also excluded were current smokers, subjects report-
ing a history of smoking within the last 3 months or
those who consumed >35 g of ethanol regularly per
day, respectively >245 g ethanol regularly per week or
more than 5 cups of coffee (or equivalent) per day.
Moreover, consumption of alcohol or xanthine-containing
food or beverages (e.g., coffee or black tea) as well as
grapefruit juice was not allowed within 48 h prior to
first administration of magnesium. Alcohol consump-
tion was determined by questioning and regular alco-
hol breath tests.
Study flow and procedures
The study consisted of a Screening Visit, an In-house
Phase and an End-of-Study Visit. Subjects were screened
for eligibility within 14 to 2 days prior to the In-house
Phase. Figure 1 presents an overview of the study schedule.
The In-house Phase included two profile days (P1 and
P2). P1 was preceded by an initial magnesium saturation
phase of 5 days, followed by one stop-of-saturation day
(S1). P1 and P2 were separated by an intermediate mag-
nesium saturation phase of 2 days, followed by another
stop-of-saturation day (S2). The End-of-Study Visit was
performed on the day after last study product adminis-
tration. The stop-of-saturation days were integrated in
the study schedule to avoid distortion of renal magne-
sium excretion on profile days by the high magnesium
load administered during the saturation phases.
During the magnesium saturation phases, five single
doses of 100 mg magnesium were to be taken at ap-
proximately 08.00 am, 10.00 am, 01.00 pm, 04.00 pm,
and 06.00 pm together with 200 mL of water of normal
Mg content (approximately 15 mg/L) each. On stop-of-
saturation days, subjects did not receive magnesium
supplementation.
In the morning of each profile day at about 08.00 am
to 09.00 am, the subjects received a single dose of
300 mg Mg in the form of Mg citrate or Mg oxide after
an overnight fast of at least 8 h. Immediately after in-
take, the subjects were to drink 200 mL of water of nor-
mal Mg content. Water was allowed until 1 h prior to
administration.
Fig. 1 Study schedule
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During the In-house Phase, all subjects received a bal-
anced, mixed diet containing approximately 300 to
400 mg magnesium per day. The diet was composed by
a dietitian according to standard nutrient tables. On
each profile day, standardized meals (i.e., identical meals)
were provided. On each profile day, starting 2 h after ad-
ministration, non-carbonated water of normal Mg con-
tent at room temperature was served.
On study days with urine sampling, subjects were re-
quested to follow a standardized drinking schedule. Sub-
jects were to drink 200 mL of water of normal Mg
content every 2 h. An additional portion of 200 mL water
was to be drunk together with lunch. On the other study
days, subjects were free to consume water of normal Mg
content in common amounts. Subjects were asked to
drink approximately 2 l a day.
Study products
The test product was Magnesium Verla® purKaps cap-
sules, containing the organic magnesium compound mag-
nesium citrate, marketed by Verla-Pharm Arzneimittel
GmbH & Co. KG, Germany. The product is also marketed
under the trade name Xenofit® Magnesiumcitrat pure in
Germany. Each capsule provides a dose of 150 mg elem-
ental magnesium.
The reference product was Biolectra® Magnesium
300 mg Kapseln capsules, containing the inorganic mag-
nesium compound magnesium oxide, manufactured by
HERMES Arzneimittel GmbH, Germany. Each capsule
provides a dose of 300 mg elemental magnesium.
For the saturation phases, capsules containing magne-
sium citrate (100 mg elemental magnesium per capsule)
were used.
All study products were supplied by Verla-Pharm
Arzneimittel GmbH & Co. KG, Germany.
Sample collection and analyses
Urine
Urine was collected over 24 h in nine fractions (0-2, 2-4,
4-6, 6-8, 8-10, 10-12, 12-14, 14-16 and 16-24 h) on stop-
of-saturation days and on profile days.
Directly after the first micturition, urine samples were
acidified with 200 μL highly purified concentrated HNO3.
After each micturition, samples were mixed and stored at
2-8 °C. The volume of each fraction was recorded and two
aliquots per fraction (5 mL each) were filled in sample
shipment tubes. Samples were stored under continuous
temperature control below -20 °C and were shipped
frozen on dry ice to the bioanalytical site (Helmholtz
Zentrum Muenchen, Neuherberg, Germany).
Urine samples were analyzed for total Mg content by
inductively coupled plasma optical emission spectrom-
etry (ICP-OES), using a “Spectro Ciros Vision” system
(Spectro-Ametek, Kleve, Germany). ICP-OES has been
established for more than 35 years for trace element
analysis in biological matrices. This technique deter-
mines elements, such as magnesium, as total element
content, independently of their physico-chemical state
(oxidation state or chemical binding form) [21, 22].
Instrumental parameters: Sample introduction was
performed by the instrument’s peristaltic pump at
1.0 mL/min and a Meinhard nebulizer which was fitted
into a cyclone spray chamber. The measured spectral
element line was: Mg 279.079 nm.
The radio frequency (RF) power was set to 1000 W;
the plasma gas was 15 L Ar/min and the nebulizer gas
was 600 mL Ar/min. Analytical quality control for Mg
determination was performed by analysis of blanks and
certified control standards (PE# N0691745, Perkin Elmer
Pure) after every ten samples. Accuracy of measure-
ments was determined according to IUPAC guidelines
[23] by analysis of an adequate certified standard refer-
ence material, BCR® 304, from the Joint Research Centre,
Institute for Reference Materials and Measurements
(IRMM) of the European Union. The found value was
1.85 ± 0.01 mmol/L and the certified value is 1.85 ±
0.03 mmol/L, resulting in an accuracy of 100%. The ser-
ial precision (N = 10) was 1.9% and the day-to-day preci-
sion (N = 10) was 2.3%.
Monocytes and lymphocytes
On profile days, blood samples (15 mL) were collected
at predose, 9 and 24 h post dose in heparinized plasma
tubes. The anticoagulated blood was diluted with 7.5 mL
phosphate buffered saline (PBS), mixed and carefully
poured into Leucosep® tubes (Greiner Bio-One, No.
227288). Samples were centrifuged for 15 min at 1000 × g
at room temperature. After centrifugation, the inter-
phase containing monocytes and lymphocytes was har-
vested and washed twice with PBS. In the end, the cells
were pelleted by centrifugation and the remaining liquid
supernatant was removed. Cell pellets were stored under
continuous temperature control below −20 °C and
shipped frozen on dry ice to the bioanalytical site (Helm-
holtz Zentrum Muenchen, Neuherberg, Germany).
Cell pellets were lysed in suprapure HNO3 and ana-
lyzed for total Mg content by ICP-OES analogously to
the urine samples.
Erythrocytes
Blood samples for determination of total Mg concentra-
tion in erythrocytes (2.7 mL for hematocrit determination
and 1.2 mL for Mg measurement in whole blood) were
taken on profile days at predose, 9 and 24 h post dose.
The blood samples were collected in closed potassium
EDTA tubes. Blood samples for Mg measurement were
stored and shipped at 2-8 °C. Samples for hematocrit
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determination were stored and shipped at room
temperature. The bioanalytical analyses were performed
by the contract laboratory Medizinisches Versorgungszen-
trum Labor Muenchen Zentrum, Munich, Germany.
Hematocrit (Hct) was measured with a particle coun-
ter and calculated by the number of erythrocytes and
their mean cellular volume. It represents the proportion
of erythrocytes in whole blood (in Vol %).
Magnesium concentration in serum (MGA) was mea-
sured directly by a clinical chemistry method. Magnesium
concentration in whole blood (MGV) was measured
directly by flame atomic absorption spectrometry. The
intra-assay precision ranged from 1.4 to 3.7% and the
inter-assay precision ranged from 3.2 to 5.2%. The
limit of detection was 0.03 mmol/L and the lower
limit of quantification was 0.07 mmol/L.
The magnesium concentration in erythrocytes (MGER)
was calculated as follows:
MGER ¼ ðMGV−

MGA  1− Hct  0:01ð Þð Þ

Þ
 Hct  0:01ð Þ in mmol=L½ 
ð1Þ
Serum
On profile days, blood samples (2.6 mL) were collected
at predose, 60 min, 2, 3, 4, 5, 6, 9 and 24 h post dose in
closed serum tubes.
Immediately after taking, the samples were incubated at
room temperature for at least 20 min but no longer than
60 min for clotting. To ensure comparability, the preferred
incubation time was 30 min. Thereafter, samples were
centrifuged at room temperature and 1700 × g for 10 min.
The complete resulting serum supernatant was then
transferred into polypropylene tubes and shipped to the
bioanalytical site (Medizinisches Versorgungszentrum
Labor Muenchen Zentrum, Munich, Germany).
Serum samples were analyzed for Mg2+ content by a
spectrophotometric method. The intra-assay precision
ranged from 0.49 to 3.7% and the inter-assay precision
ranged from 0.30 to 3.33%. The lower limit of quantifi-
cation was 0.29 mmol/L.
Statistics
Sample size calculation
Considering an analysis of variance (ANOVA) for a dif-
ference of means in a 2 × 2 cross-over, a sample size of
N = 18 was determined to reach 80% power for the pri-
mary endpoint. The calculation was performed using
nQuery Advisor + nTerim 2.0® software with the following
assumptions: mean difference = 5%, standard deviation
(SD) of difference = 8%, power ≥80%.
In order to allow for withdrawals, at least 20 subjects
were to be randomized.
Randomization
On Profile Day 1, subjects were randomly assigned to 1 of
the 2 following sequences of study product administration:
Sequence 1 - Period 1: Biolectra® Magnesium 300 mg
Kapseln; Period 2: Magnesium Verla® purKaps.
Sequence 2 - Period 1: Magnesium Verla® purKaps;
Period 2: Biolectra® Magnesium 300 mg Kapseln.
The randomization code for assigning random num-
bers to sequence groups was created using SAS® 9.4
software.
Statistical analyses
At first, the renally excreted Mg quantity during the
interval of 24 h after Mg administration (Ae 0-24h) was
calculated from the nine urine fractions taken and was
analyzed by descriptive statistics for each group.
In order to compare the bioavailability of the test and
reference product, an ANOVA was performed. Based on
the result of a Kolmogorov-Smirnov data normality test,
raw data or log-transformed (natural logarithm) values
were used for the ANOVA. The ANOVA was performed
at the 5% level [P < 0.05], two-sided, using SAS® 9.4 soft-
ware. Effects considered in the ANOVA model were: study
product, sequence, period and subject within sequence.
Statistical significance at a level of 5% was given if the
95% confidence interval (CI) of the adjusted mean differ-
ence resulting from the ANOVA did not include zero,
respectively if the adjusted mean ratio resulting from the
ANOVA with log-transformed data (log-ANOVA) did
not include 1.
The statistical analyses of the Mg concentrations in a
subset of leukocytes, in erythrocytes and in serum were




A total of 24 subjects signed informed consent and were
screened for this study. One subject did not meet eligi-
bility criteria and three subjects withdrew consent after
Visit 1. Twenty male Caucasian subjects, who fulfilled all
the inclusion criteria and in whom no exclusion criterion
was present were included into the study and were ran-
domized. All 20 subjects completed the study.
All 20 subjects were healthy male Caucasians. Age
ranged from 19 to 42 years, with the statistical mean (SD)
at 28.3 (5.97) years. Height varied from 171 to 193 cm,
with the statistical mean (SD) at 182.1 (5.61) cm. Weight
was between 63.0 and 88.6 kg, with the statistical mean
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(SD) at 77.4 (7.63) kg. BMI was between 18.8 and 28.1,
with the statistical mean (SD) at 23.4 (2.54). Key demo-
graphic characteristics of the study subjects are sum-




On stop-of-saturation days, the mean (SD) Ae 0-24h
of magnesium before administration of Biolectra®
Magnesium 300 mg Kapseln was 6.9 (1.23) mmol and
7.0 (1.67) mmol before administration of Magnesium
Verla® purKaps (please refer to Table 1, Fig. 2 and
Additional file 2: Figure S1). The ANOVA indicated a
similar baseline between groups, with an adjusted mean
difference of 0.145 mmol (95% CI ranged from −0.276 to
0.565 mmol; p = 0.4784). Therefore, it can be concluded
that the subjects’ Mg-pools were filled to about the same
extent before administration of either of the study prod-
ucts and magnesium bioavailability via renal elimination
could be compared reliably.
On profile days, the primary parameter Ae 0-24h of
magnesium was higher for Magnesium Verla® purKaps,
with mean (SD) of 7.2 (1.48) mmol as compared to
6.7 (1.43) mmol after administration of Biolectra® Magne-
sium 300 mg Kapseln (please refer to Table 1).
The data did not need to be log-transformed prior to
the ANOVA as the results of the Kolmogorov-Smirnov
normality test had not led to a rejection of the null hy-
pothesis of data normality. As presented in Table 1 and
Fig. 2, the ANOVA to compare Ae 0-24h for both study
products revealed an adjusted mean difference of
0.565 mmol, which was statistically significant at the
5% level (95% CI of 0.212 to 0.918 mmol, p = 0.0034).
Monocytes and lymphocytes
Mean (SD) magnesium concentration in monocytes and
lymphocytes before administration of Biolectra® Magne-
sium 300 mg Kapseln was 0.11 (0.034) mg/L and there-
fore largely identical to the value measured before
administration of Magnesium Verla® purKaps, with
0.12 (0.043) mg/L (please refer to Table 2 and Fig. 3).
The data did not need to be log-transformed prior to
the ANOVA as the results of the Kolmogorov-Smirnov
normality test had not led to a rejection of the null hy-
pothesis of data normality.
The ANOVA to compare the magnesium concentra-
tion in monocytes and lymphocytes revealed adjusted
mean differences, which were not statistically significant
at the 5% level (Table 2) at all time points measured,
with point estimates of 0.013 mg/L for predose (95% CI
of −0.004 to 0.030 mg/L; p = 0.1235), 0.005 mg/L for 9 h
post dose (95% CI of −0.012 to 0.002 mg/L; p = 0.1614),
and −0.007 mg/L for 24 h post dose (95% CI of −0.018
to 0.005 mg/L; p = 0.2424).
Erythrocytes
Mean (SD) magnesium concentration in erythrocytes be-
fore administration of Biolectra® Magnesium 300 mg
Kapseln was 2.27 (0.400) mmol/L and therefore largely
identical to the values measured before administration
of Magnesium Verla® purKaps with 2.24 (0.439) mmol/L
(please refer to Table 2 and Fig. 4).
The data did not need to be log-transformed prior to
the ANOVA as the results of the Kolmogorov-Smirnov
normality test had not led to a rejection of the null hy-
pothesis of data normality.
The ANOVA to compare the magnesium concentra-
tion in erythrocytes revealed adjusted mean differences,
which were not statistically significant at the 5% level
(Table 2) at all time points measured, with point esti-
mates of −0.022 mmol/L for predose (95% CI of −0.233
to 0.189 mmol/L; p = 0.8294), −0.001 mmol/L for 9 h
post dose (95% CI of −0.116 to 0.113 mmol/L; p = 0.9784),
and 0.028 mmol/L for 24 h post dose (95% CI of −0.106
to 0.162 mmol/L; p = 0.6655).
Serum
Mean (SD) serum Mg concentration before administra-
tion of Biolectra® Magnesium 300 mg Kapseln was
0.87 (0.042) mmol/L and therefore identical to the values
Table 1 Analysis of renally eliminated magnesium (Ae 0-24h) in mmol
Time point Study product Mean (SD) ANOVA
Adj. mean difference 95% CI p-value
Stop-of-saturation Biolectraa 6.9 (1.23) 0.145 (−0.276, 0.565) 0.4784
Verlaa 7.0 (1.67)
Profile day Biolectra 6.7 (1.43) 0.565 (0.212, 0.918) 0.0034*
Verla 7.2 (1.48)
Adjusted mean difference, 95% CI and p-value are based on an ANOVA model with study product, sequence, period and subject within sequence as considered
effects. Statistical significance at a level of 5% is given if the 95% confidence interval of the adjusted mean difference does not include 0, respectively if the p-
value is <0.05. Statistical significance is denoted by an asterisk (*)
CI confidence interval, SD standard deviation; Biolectra Biolectra® Magnesium 300 mg Kapseln; Verla Magnesium Verla® purKaps
aHere, the name of the study product taken on the following profile day is provided. No study product was given on stop-of-saturation days
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Fig. 2 Difference in Ae 0-24h of magnesium on stop-of-saturation days and on profile days. The difference in Ae 0-24h of magnesium is significantly
higher on profile days than on stop-of-saturation days. Stop-of-saturation: The difference in Ae 0-24h of magnesium between both stop-of-saturation
days (i.e., Ae 0-24h before the administration of Magnesium Verla® purKaps minus Ae 0-24h before the administration of Biolectra® Magnesium 300 mg
Kapseln); Profile day: The difference in Ae 0-24h of magnesium between both profile days (i.e., Ae 0-24h after administration of Magnesium Verla® purKaps
minus Ae 0-24h after administration of Biolectra® Magnesium 300 mg Kapseln); Biolectra = Biolectra® Magnesium 300 mg Kapseln; Verla=Magnesium Verla®
purKaps. The bottom and top edges of the box indicate the intra-quartile range (IQR), i.e., the range of values between the first and third quartiles (the
25th and 75th percentiles). The diamond inside the box indicates the mean value, whereas the horizontal line represents the median
value. The whiskers are drawn from the box to the most extreme point that is less than or equal to 1.5 times the IQR. Values outside of
this range are displayed as closed circles
Table 2 Analysis of magnesium concentration in monocytes and lymphocytes (in mg/L) and in erythrocytes (in mmol/L)
Parameter Time point Study product Mean (SD) ANOVA
Adj. mean difference 95% CI p-value
Mg in monocytes and lymphocytes predose Biolectra 0.11 (0.034) 0.013 (−0.004, 0.030) 0.1235
Verla 0.12 (0.043)
9 h Biolectra 0.12 (0.034) −0.005 (−0.012, 0.002) 0.1614
Verla 0.11 (0.040)
24 h Biolectra 0.11 (0.029) −0.007 (−0.018, 0.005) 0.2424
Verla 0.11 (0.023)
Mg in erythrocytes Predose Biolectra 2.27 (0.400) −0.022 (−0.233, 0.189) 0.8294
Verla 2.24 (0.439)
9 h Biolectra 2.09 (0.287) −0.001 (−0.116, 0.113) 0.9784
Verla 2.09 (0.269)
24 h Biolectra 2.10 (0.353) 0.028 (−0.106, 0.162) 0.6655
Verla 2.13 (0.318)
CI confidence interval, Mg magnesium, SD standard deviation; Biolectra = Biolectra® Magnesium 300 mg Kapseln; Verla =Magnesium Verla® purKaps. Adjusted mean
difference, 95% CI and p-value are based on an ANOVA model with study product, sequence, period and subject within sequence as considered effects. Statistical
significance at a level of 5% is given if the 95% confidence interval of the adjusted mean difference does not include 0, respectively if the p-value is <0.05
Kappeler et al. BMC Nutrition  (2017) 3:7 Page 7 of 12
Fig. 3 Mean (SEM) magnesium concentration at different time points in monocytes and lymphocytes. Biolectra = Biolectra® Magnesium 300 mg
Kapseln; Verla =Magnesium Verla® purKaps. The standard error of the mean (SEM) is depicted by bars
Fig. 4 Mean (SEM) magnesium concentration at different time points in erythrocytes. Biolectra = Biolectra® Magnesium 300 mg Kapseln;
Verla = Magnesium Verla® purKaps. The standard error of the mean (SEM) is depicted by bars
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measured before administration ofMagnesium Verla® pur-
Kaps with 0.87 (0.042) mmol/L (please refer to Table 3).
The ANOVA with log-transformed data (log-ANOVA)
indicated a similar baseline between groups, with an
adjusted mean ratio of magnesium in serum of 1.00
(95% CI ranged from 0.98 to 1.01; p = 0.5169) at pre-dose.
Starting from 2 h post dose, the mean magnesium
concentration in serum was higher for Magnesium
Verla® purKaps than for Biolectra® Magnesium 300 mg
Kapseln until 24 h after dosing when serum magnesium
concentrations for both products returned to the pre-
dose value (Fig. 5).
As the Kolmogorov-Smirnov normality test showed
that the data were not normally distributed at the time
points of 2 and 4 h after administration of magnesium,
the data used for the ANOVA were log-transformed
(log-ANOVA). For the time points 2, 3, 4, 5 and 6 h
after administration, the log-ANOVA to compare serum
magnesium concentrations resulted in adjusted mean ra-
tios, which were statistically significant at the 5% level,
showing superior magnesium absorption for Magnesium
Verla® purKaps (please refer to Table 3). Point estimates
were 1.03 for 2 h post dose (95% CI of 1.01 to 1.04;
p = 0.0008), 1.03 for 3 h post dose (95% CI of 1.02 to
1.04; p < .0001), 1.03 for 4 h post dose (95% CI
of 1.01 to 1.04; p = 0.0016), 1.03 for 5 h post dose
(95% CI of 1.01 to 1.04; p = 0.0036), and 1.02 for 6 h
post dose (95% CI of 1.01 to 1.04; p = 0.0026).
No statistical significance was shown for the time
points 60 min, 9 h and 24 h after administration. Point
estimates of adjusted mean ratios were 1.01 for 60 min
post dose (95% CI of 1.00 to 1.02; p = 0.1991), 1.02 for
9 h (95% CI of 1.00 to 1.03; p = 0.0979), and 1.00 for
24 h post dose (95% CI of 0.99 to 1.01; p = 0.8756).
Discussion
The aim of this study was to investigate the bioavailabil-
ity of Mg citrate, an organic Mg compound, and Mg
oxide, an inorganic Mg compound after single-dose ad-
ministration following Mg saturation.
Validity of the study design, based on the measure-
ment of the renally excreted amount of magnesium, was
shown by reproducible baseline Mg excretion after sat-
uration in either study product sequence, thus underlin-
ing the reliability of the study results.
After administration, the primary parameter Ae 0-24h
of magnesium was higher for Mg citrate than for Mg
oxide. The comparison of Ae 0-24h for both products by
ANOVA showed an adjusted mean difference that was
statistically significant, demonstrating that the organic
Mg compound Mg citrate of the test product Magne-
sium Verla® purKaps was superior to the inorganic Mg
Table 3 Analysis of serum magnesium concentration (in mmol/L)
Time point Study product Mean (SD) Log-ANOVA
Adj. mean ratio 95% CI p-value
Predose Biolectra 0.87 (0.042) 1.00 (0.98, 1.01) 0.5169
Verla 0.87 (0.042)
60 min Biolectra 0.88 (0.043) 1.01 (1.00, 1.02) 0.1991
Verla 0.88 (0.041)
2 h Biolectra 0.89 (0.040) 1.03 (1.01, 1.04) 0.0008*
Verla 0.92 (0.037)
3 h Biolectra 0.85 (0.041) 1.03 (1.02, 1.04) <.0001*
Verla 0.88 (0.040)
4 h Biolectra 0.88 (0.045) 1.03 (1.01, 1.04) 0.0016*
Verla 0.90 (0.040)
5 h Biolectra 0.87 (0.044) 1.03 (1.01, 1.04) 0.0036*
Verla 0.89 (0.043)
6 h Biolectra 0.86 (0.044) 1.02 (1.01, 1.04) 0.0026*
Verla 0.88 (0.039)
9 h Biolectra 0.89 (0.038) 1.02 (1.00, 1.03) 0.0979
Verla 0.90 (0.048)
24 h Biolectra 0.88 (0.049) 1.00 (0.99, 1.01) 0.8756
Verla 0.88 (0.043)
CI confidence interval, Mg magnesium, SD standard deviation; Biolectra = Biolectra® Magnesium 300 mg Kapseln; Verla =Magnesium Verla® purKaps. Adjusted mean
ratio, 95% CI and p-value are based on an ANOVA model with study product, sequence, period and subject within sequence as considered effects. Statistical
significance at a level of 5% is given if the 95% confidence interval of the adjusted mean ratio does not include 1, respectively if the p-value is <0.05. Statistical
significance is denoted by an asterisk (*)
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compound Mg oxide of the reference product Biolectra®
Magnesium 300 mg Kapseln in terms of bioavailability.
This result is confirmed by serum Mg concentrations
which were statistically significantly higher for Magne-
sium Verla® purKaps at the time points 2, 3, 4, 5 and 6 h
after administration, showing superior Mg absorption.
No statistically significant difference between Mg citrate
and Mg oxide was shown when comparing intracellular
magnesium concentrations (in monocytes and lympho-
cytes or erythrocytes). The determination of intracellular
Mg concentrations may possibly not be a suitable model
for the assessment and quantification of a quick wash-in
of this mineral nutrient in form of a single-dose admin-
istration. The reliability of intracellular Mg concentra-
tions after long-term Mg supplementation remains to
be established.
Since the homeostatic regulation of serum Mg is extra-
ordinarily effective, the absorbed Mg disappears very
quickly from the circulation; i.e., the absorbed Mg is dis-
tributed into body stores and excreted renally (in this
case, after saturation of the body stores, the absorbed
magnesium will not be stored, but excreted renally).
Therefore, it is commonly assumed that changes of
serum Mg concentration after a single oral magnesium
dose are difficult to measure [15].
To date, two studies have directly compared the bio-
availability of Mg citrate and Mg oxide preparations of
similar elemental Mg content [11, 14]. Although Walker
et al. [14] showed that the administration of a single
dose of Mg citrate led to significantly higher serum Mg
concentrations when compared to Mg oxide, they could
not report a statistically significant difference in bioavail-
ability between both magnesium preparations when
comparing renally excreted magnesium after single-dose
administration.
The present study provides more consistent results
concerning the bioavailability of both Mg compounds.
This might be due to the systematic Mg saturation of
the study subjects’ Mg-pools before single-dose Mg ad-
ministration and the standardization of their dietary Mg
intake. Both of these measures were not taken in the
study by Walker et al. [14] which could explain the dis-
crepancies in the results.
The present study confirms the results of Lindberg et
al. [11], who also found a higher Mg elimination, and
hence better absorption after supplementation with Mg
citrate compared to Mg oxide.
The present results further support the general scien-
tific opinion that the inorganic Mg compound Mg oxide
is not as easily absorbable as organic Mg compounds
[24]. Several studies showed that organic Mg com-
pounds, such as Mg aspartate-hydrochloride or Mg lac-
tate, generally have a higher bioavailability than Mg
oxide [12, 13]. Therefore, the supplementation with Mg
citrate, similar to other organic magnesium compounds,
may be more suitable to achieve an optimal dietary mag-
nesium intake in comparison to the supplementation
with Mg oxide.
Fig. 5 Mean (SEM) magnesium concentration at different time points in serum. Biolectra = Biolectra® Magnesium 300 mg Kapseln;
Verla = Magnesium Verla® purKaps. The standard error of the mean (SEM) is depicted by bars
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Although the present study was conducted exclusively
in male Caucasian subjects, the results are transferable
to females. To date, no scientific evidence indicates that
the intestinal Mg absorption differs between the sexes. It
has been shown, however, that estrogen influences Mg
distribution and excretion [20]. Since the concentration
and fluctuation of this hormone is higher in females,
only male subjects were included in this study to
standardize the measurement of the renally eliminated
magnesium quantity which served as an indirect meas-
ure of Mg absorption and therefore bioavailability.
Conclusions
In summary, the present study confirms former study
results showing a higher bioavailability of the organic
Mg compound Mg citrate over the inorganic Mg com-
pound Mg oxide. It can be concluded that Mg citrate,
similar to other organic Mg compounds, may be more
suitable than Mg oxide to optimize the dietary magne-
sium intake which, if too low, is associated with an in-
creased risk for the development of several disorders.
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